Subcutaneous Tumor Articles & Analysis
2 news found
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. ...
We are announcing the launch of our next generation 3D scanner for subcutaneous tumors on mice and rats. We simply named it TumorImager 2TM. ...